On Invalid Date, Zevra Therapeutics (NASDAQ: ZVRA) reported Q4 2023 earnings per share (EPS) of -$0.40, up 350% year over year. Total Zevra Therapeutics earnings for the quarter were -$15.15 million. In the same quarter last year, Zevra Therapeutics's earnings per share (EPS) was $0.16.
As of Q2 2024, Zevra Therapeutics's earnings has grown year over year. Zevra Therapeutics's earnings in the past year totalled -$46.05 million.
What is ZVRA's earnings date?
Zevra Therapeutics's earnings date is Invalid Date. Add ZVRA to your watchlist to be reminded of ZVRA's next earnings announcement.
What was ZVRA's revenue last quarter?
On Invalid Date, Zevra Therapeutics (NASDAQ: ZVRA) reported Q4 2023 revenue of $13.22 million up 553.66% year over year. In the same quarter last year, Zevra Therapeutics's revenue was $2.02 million.
What was ZVRA's revenue growth in the past year?
As of Q2 2024, Zevra Therapeutics's revenue has grown 170.26% year over year. This is 20.74 percentage points higher than the US Biotechnology industry revenue growth rate of 149.51%. Zevra Therapeutics's revenue in the past year totalled $27.46 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.